NICE Surgical Awarded Additional Purse-String Stapler Associated U.S. Patent
MWN-AI** Summary
NICE Surgical Solutions Pte Ltd, a clinical-stage medical device company based in Singapore, has received U.S. Patent No. 12,661,097 B2 for its innovative extracting device designed to work alongside its unique purse-string stapler. This significant development aims to enhance colorectal surgical procedures by enabling the extraction of excised colon tissue through the anal canal, minimizing the need for surgical incisions—a breakthrough that potentially reduces infection risks and improves patient recovery times.
The patented extraction device and its introducer are critical components that facilitate full intracorporeal anastomosis, allowing both the surgical procedure and the removal of tissue to be performed within the body without external abdominal incisions. This aligns with NICE Surgical’s mission to enhance the quality of life for patients through advanced medical technologies.
Eric Haas, MD, Co-founder and Chief of Colorectal Surgery at Houston Methodist Hospital, emphasized that true innovation in colorectal surgery goes beyond simply integrating new technologies; it focuses on promoting safer surgical practices and faster recovery for patients. Haim Brosh, CEO of Trendlines Medical Singapore, noted that the issuance of this patent underscores NICE Surgical's commitment to developing superior medical solutions.
As a part of The Trendlines Group Ltd, which invests in medtech and agrifood innovations, NICE Surgical represents a growing portfolio aiming to transform early-stage technologies into impactful and sustainable medical advancements. This latest patent marks a significant milestone in NICE Surgical's ongoing efforts to innovate in the field of colorectal surgery, potentially setting new standards for the industry.
MWN-AI** Analysis
NICE Surgical Solutions Pte Ltd's recent award of U.S. Patent No. 12,661,097 B2 for its innovative purse-string stapler device represents a significant advance in the field of minimally invasive colorectal surgery. This development not only mitigates the necessity for abdominal incisions but also enhances patient safety by reducing the risk of postoperative infections.
From an investment perspective, NICE’s patent validates its strong intellectual property portfolio, positioning the company for growth within an expanding medtech landscape. As surgical procedures progress towards minimally invasive techniques, NICE’s technology aligns with broader industry trends aimed at improving patient outcomes and reducing healthcare costs.
The collaboration with Trendlines Medical Singapore, an experienced player in the medtech sector, adds further credibility to NICE’s growth potential. Their shared vision of innovation emphasizes the importance of developing safer surgical instruments, which is crucial in a healthcare environment increasingly focused on optimizing surgical practices. As NICE Surgical prepares to commercialize its technology, potential investors should consider analyzing the market demand for minimally invasive surgical solutions, especially in colorectal procedures, which represent a substantial volume of surgeries performed globally.
Moreover, with the increasing emphasis on patient-centric approaches in healthcare, NICE’s products could garner attention from healthcare providers seeking to enhance their surgical offerings. Investors should also monitor NICE Surgical's positioning regarding competing technologies and any strategic partnerships that may enhance its market reach.
In conclusion, stakeholders looking for opportunities in the medtech field should closely follow NICE Surgical's developments. The combination of innovative technology and strategic backing from Trendlines offers potential for substantial returns as the demand for advanced medical solutions continues to rise.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PR Newswire
Enables natural orifice extraction of tissue without surgical incision
SINGAPORE, July 20, 2026 /PRNewswire/ -- NICE Surgical Solutions Pte Ltd ("NICE Surgical"), a clinical-stage medical device company pioneering full intracorporeal anastomosis surgical instruments, has been granted U.S. Patent No. 12,661,097 B2, for its extracting device used in conjunction with its novel purse-string stapler, generally eliminating the need for surgical incisions in colorectal surgery.
The patent covers NICE's extraction device design, along with its introducer that, when used with NICE's purse-string stapler, allows extraction of excised colon tissue through the intra-anal canal. The award of the patent validates NICE Surgical's strength in developing proprietary medical solutions to improve quality of life by mitigating the risk of infection prevalent to these surgeries.
The patented technology, together with its patented purse-string stapler, enables colorectal surgery and retrieval of excised tissue to be completed fully intracorporeally and minimally invasively, without an incision to the abdomen, as currently practiced.
NICE Surgical is a portfolio company of Trendlines Medical Singapore Pte Ltd ("Trendlines Medical Singapore"), a subsidiary of The Trendlines Group Ltd (SGX: 42T) (OTCQX: TRNLY), ("Trendlines"), an investment company focused on medtech and agrifood innovation.
"We are excited that two of our innovative solutions were awarded U.S. patents in quick succession. Innovation in colorectal surgery is not about adopting the newest technology—it is about advancing safer surgery, faster recovery, and better lives for every patient," commented Co-founder and Inventor, Eric Haas, MD, Chief of Colorectal Surgery, Houston Methodist Hospital.
Haim Brosh, CEO of Trendlines added, "NICE surgical truly embraces a keen innovative mindset and delivered the utmost in terms of design and development of its purse-string stapler and its extracting device. The award of the U.S. patent cements the resolve of NICE Surgical in bringing better solutions to the practice of medicine."
About The Trendlines Group Ltd.
The Trendlines Group (SGX: 42T) (OTCQX: TRNLY) invests in and develops innovations in agrifood and medtech, transforming early-stage technologies into impactful businesses. With operations in Israel and Singapore, Trendlines combines capital, expertise, and strategic partnerships to drive growth, advance global sustainability, and create long-term value for shareholders.
About NICE Surgical Solutions Pte Ltd
NICE Surgical is developing a stapling device that serves to divide the bowel at the proximal and distal level of resection as well as place a 'purse-string suture' to prepare the bowel for the Intra Corporeal Anastomosis (ICA). The stapling device accomplishes two critical tasks by simultaneously stapling closed the specimen while applying a 'purse-string suture' to the portion of the bowel to be used for an end-to-end circular stapled anastomosis.
Media contact:
Eric Loh
CEO Trendlines Medical Singapore
eric@trendlines.com
SOURCE NICE Surgical Solutions Pte Ltd
FAQ**
How does the newly patented extracting device from NICE Surgical Solutions, a portfolio company of Trendlines Group Ltd TRNGF, enhance the safety and efficacy of colorectal surgeries compared to traditional methods?
In what ways does the patented technology, including the purse-string stapler developed by NICE Surgical Solutions under Trendlines Group Ltd TRNGF, mitigate the risk of infection during surgical procedures?
What future implications does the U.S. Patent No. 12,661,097 B2 for NICE Surgical Solutions signify for the medtech investments made by Trendlines Group Ltd TRNGF, especially in the colorectal surgery market?
How does the innovative approach of NICE Surgical's devices, backed by Trendlines Group Ltd TRNGF, align with current trends in minimally invasive surgical techniques and patient recovery?
**MWN-AI FAQ is based on asking OpenAI questions about Trendlines Group Ltd ADR (OTC: TRNLY).
NASDAQ: TRNLY
TRNLY Trading
0.0% G/L:
$2.10 Last:
1,500 Volume:
$2.10 Open:
TRNLY Latest News
